Literature DB >> 7002831

Viloxazine: a review of the literature.

T A Ban, J P McEvoy, W H Wilson.   

Abstract

In animal pharmacological studies viloxazine has shown similarities to imipramine. The antidepressant effects of the substance were independently recognized in seven uncontrolled clinical trials and verified in 11 published standard controlled clinical studies in which viloxazine in the dosage range from 150- to 300-mg dosage was equal in overall therapeutic efficacy to imipramine and amitriptyline, but produced a lower incidence of side effects.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7002831     DOI: 10.1159/000468422

Source DB:  PubMed          Journal:  Int Pharmacopsychiatry        ISSN: 0020-8272


  4 in total

1.  Pharmacokinetics of the antidepressant drug viloxazine in normal subjects and in epileptic patients receiving chronic anticonvulsant treatment.

Authors:  F Pisani; A Fazio; E Spina; C Artesi; B Pisani; M Russo; R Trio; E Perucca
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

2.  Cholinergic neurotransmission seems not to be involved in depression but possibly in personality.

Authors:  J Fritze; M Lanczik; E Sofic; M Struck; P Riederer
Journal:  J Psychiatry Neurosci       Date:  1995-01       Impact factor: 6.186

3.  Age-related differences in kinetics and side-effects of viloxazine in man and their clinical implications.

Authors:  A C Altamura; T Melorio; G Invernizzi; F Colacurcio; R Gomeni
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

4.  Impact of Paroxetine, a Strong CYP2D6 Inhibitor, on SPN-812 (Viloxazine Extended-Release) Pharmacokinetics in Healthy Adults.

Authors:  Zhao Wang; Alisa R Kosheleff; Lilian W Adeojo; Oyinkansola Odebo; Toyin Adewole; Peibing Qin; Vladimir Maletic; Stefan Schwabe; Azmi Nasser
Journal:  Clin Pharmacol Drug Dev       Date:  2021-05-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.